Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jiamei Liu is active.

Publication


Featured researches published by Jiamei Liu.


Heart | 2015

Relationship between fine particulate air pollution and ischaemic heart disease morbidity and mortality

Wuxiang Xie; Li G; Dong Zhao; Xie X; Wei Z; Wei Wang; Miao Wang; Liu W; Jiayi Sun; Zhangrong Jia; Qian Zhang; Jiamei Liu

Objective To assess the relationship between fine particulate matter (PM2.5) concentration and ischaemic heart disease (IHD) morbidity and mortality. Methods A time-series study conducted in Beijing from 1 January 2010 to 31 December 2012. Data on 369 469 IHD cases and 53 247 IHD deaths were collected by the Beijing Monitoring System for Cardiovascular Diseases, which covers all hospital admissions and deaths from IHD from Beijings population of 19.61 million. Results The mean daily PM2.5 concentration was 96.2 μg/m3 with a range from 3.9 to 493.9 μg/m3. Only 15.3% of the daily PM2.5 concentrations achieved WHO Air Quality Guidelines target (25 μg/m3) in the study period. The dose–response relationships between PM2.5 and IHD morbidity and mortality were non-linear, with a steeper dose–response function at lower concentrations and a shallower response at higher concentrations. A 10 μg/m3 increase in PM2.5 was associated with a 0.27% (95% CI 0.21 to 0.33%, p<2.00×10−16) increase in IHD morbidity and a 0.25% (95% CI 0.10 to 0.40%, p=1.15×10−3) increase in mortality on the same day. During the 3 years, there were 7703 cases and 1475 deaths advanced by PM2.5 pollution over expected rates if daily levels had not exceeded the WHO target. Conclusions PM2.5 concentration was significantly associated with IHD morbidity and mortality in Beijing. Our findings provide a rationale for the urgent need for stringent control of air pollution to reduce PM2.5 concentration.


PLOS ONE | 2014

The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors.

Jiamei Liu; Yidan Wang; Mulei Chen; Wen-Shu Zhao; Xin Wang; Hua Wang; Zhiyong Zhang; Juan Zhang; Lin Xu; Jin Chen; Xinchun Yang; Lin Zhang

Background Peripartum cardiomyopathy (PPCM) is characterized by left ventricular systolic dysfunction and heart failure. However, its pathogenesis is not clear. Our preliminary study revealed that autoantibodies against β1-adrenergic receptors (β1R-AABs) and M2-muscarinic receptors (M2R-AABs) participated in heart failure regardless of primary heart disease. Whether β1R-AABs and M2R-AABs participate in the pathogenesis of PPCM is still unknown. Methods Totally 37 diagnosed PPCM patients and 36 normal pregnant women were enrolled in this study. Clinical assessment and 2-dimensional echocardiographic studies as well as the measurement of β1R-AABs or M2R-AABs by enzyme linked immunosorbent assay (ELISA) were performed. Results The positive rates for β1R-AABs and M2R-AABs were 59.5% (22/37) and 45.9% (17/37) in PPCM patients, and 19.4% (7/36) (P<0.001) and 16.67% (6/36) (P<0.001) in normal pregnant women, respectively. Both β1R-AABs and M2R-AABs had a positive correlation with serum expression level of NT-proBNP, left ventricular dimension and NYHA FC (rs: 0.496–0.892, P<0.01). In addition, a negative correlation between the activity of β1R-AABs and M2R-AABs and LVEF, LVFS was observed (rs: −0.488–0.568, P<0.01). Moreover, autoantibodies against cardiovascular receptors increased the risk of the onset of PPCM (OR = 18.786, 95% confidence interval 1.926–183.262, P = 0.012). Conclusions The β1R-AABs and M2R-AABs reveal a significant elevation and are correlated with the increased left ventricular dimension and worse cardiac contraction function. The autoantibodies of cardiovascular receptors are independent risk factors for the onset of PPCM.


Leukemia & Lymphoma | 2018

Autoantibodies against β1-adrenergic receptor: response to induction therapy with bortezomib-containing regimens for multiple myeloma patients

Wen Gao; Wen-Jia Guo; Dong-Yan Hou; Guangzhong Yang; Yin Wu; Yanchen Li; Yun Leng; Yu Tang; Lin Xu; Jiamei Liu; Hua Wang; Xin Wang; Juan Zhang; Wen-Shu Zhao; Wenming Chen; Lin Zhang

Abstract This study aims to investigate the predictive value of pre-chemotherapy β1R-AABs by evaluating the response of newly diagnosed symptomatic multiple myeloma (MM) patients to their treatment with a bortezomib-containing regimen. Forty-five de novo MM patients and 50 normal controls (NCs) were prospectively enrolled in this study. Serum titers of β1R-AABs were detected by ELISA. These 45 MM patients were divided into two groups (positive and negative groups) according to their β1R-AABs. Follow-up examinations were performed on these patients during chemotherapy induction. The final analysis covered all 45 MM patients, including 19 patients who were positive for MM and 26 patients who were negative for MM. Multivariate analysis revealed that pre-chemotherapy β1R-AABs are possibly independent predictors for less than very good partial response (VGPR) after the bortezomib-containing regimen treatment (odds ratio: 5.967, 95% confidence interval: 1.513–23.531; p = .011). This study demonstrates for the first time that the presence of β1R-AABs is associated with MM. Pre-chemotherapy β1R-AABs are independent predictors for less than VGPR in de novo MM patients after the bortezomib-containing regimen was administrated. Bortezomib might not significantly give rise to cardiac impairment in MM patients.


The Cardiology | 2018

The Effect of Autoantibody against M 2 -Muscarinic Acetylcholine Receptor in Heart Failure Patients on Digoxin Treatment

Dong-Yan Hou; Zhenping Fan; Lin Xu; Hua Wang; Zhiyong Zhang; Guiling Ma; Xiao-Rong Xu; Xin Wang; Juan Zhang; Jiamei Liu; Lin Zhang

Background: Autoantibody against M2-muscarinic acetylcholine receptor (anti-M2AChR) has a biological effect similar to a vagus agonist. Digoxin has a function of vagus nervous system stimulation. We hypothesized that anti-M2AChR is highly correlated with digoxin in patients with chronic heart failure (CHF). Methods: Synthetic M2AChR peptides served as the target antigen in an ELISA were used to screen the sera of 80 CHF patients, who were separated into a negative (–) or positive (+) anti-M2AChR group according to their anti-M2AChR reactivity. Echocardiography and serum digoxin concentration (SDC) were performed at baseline and after 1 year of digoxin in combination with the standard treatment regime. The end-point events were compared over 1 year of follow-up. Results: Seventy-two CHF patients completed the final data analysis, including 32 (+)anti-M2AChR and 40 (–)anti-M2AChR patients. The resting heart rate of the positive group was higher than that of the negative group at baseline (p < 0.05; 89.0 ± 1.6 vs. 83.8 ± 1.1 bpm). Both groups showed improvement in the left ventricular end-diastolic and end-systolic dimensions and ejection fraction with digoxin in combination with the standard treatment regime for 1 year (all p < 0.01). However, the 32 patients with (–)anti-M2AChR had greater improvements than the 40 patients with (+)anti-M2AChR, and this was accompanied by a marked decrease of rehospitalization (all p < 0.01) but not of cardiovascular mortality after 1 year. The SDC of patients with (–)anti-M2AChR was significantly lower than that of patients with (+)anti-M2AChR (p < 0.05; 0.63 ± 0.05 vs.1.16 ± 0.06 ng/mL) and had a positive correlation with anti-M2AChR (r = 0.81, p < 0.001). Conclusion: These results suggested that anti-M2AChR could be a useful biomarker of vagus nerve overactivation and is associated with a poor response to digoxin treatment in CHF patients.


Life Sciences | 2018

A severity index study of long-term prognosis in patients with chronic heart failure

Xiao-Rong Xu; Xian-Chen Meng; Xin Wang; Dong-Yan Hou; Yan-Hong Liang; Zhiyong Zhang; Jiamei Liu; Juan Zhang; Lin Xu; Hua Wang; Wen-Shu Zhao; Lin Zhang

Aims: The present study describes the derivation and validation of the Chronic Heart Failure Severity Index (CHFSI). Main methods: The CHFSI was derived using data obtained from a single‐center prospective cohort study (2000–2014) that enrolled 756 patients. Logistic regression was used to identify independent predictors of mortality and quality of life over a 15‐year follow‐up period. Key findings: The score was validated at the first 5‐year (n = 644), second 5‐year (n = 364), and third 5‐year (n = 262). Independent predictors of mortality were older age (OR = 2.04, P < 0.001), etiology score (OR = 2.61, P < 0.001), faster heart rate (OR = 1.46, P = 0.027), higher systolic blood pressure (OR = 2.35, P < 0.001), and left ventricular ejection fraction ≤45% (OR = 1.97, P = 0.018). The derived CHFSI predicted the mortality, and the AUC for the logistic model was 0.78 (95% confidence interval = 0.74–0.81, P < 0.001). Based on the logistic model, an integer scoring system was derived. Patients were classified into three groups: low risk (0–7 points), intermediate risk (8–11 points) and high risk (≥12 points) groups. The cumulative mortality for 15 years was 45.5% (125/275), 84.0% (204/243), and 100% (99/99), respectively (P < 0.001). The 6‐min walk test revealed a significant difference in quality of life among patients in the low, medium and high risk groups (all, P < 0.0001). Significance: The CHFSI is a very useful clinical predictive tool that identifies patients at risk of future mortality and their quality of life across healthcare systems.


International Journal of Molecular Medicine | 2018

Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension

Jia Liu; Jiamei Liu; Linying Shi; Fan Zhang; Liping Yu; Xinchun Yang; Jun Cai

The present study aimed to explore microRNA-126 (miR-126) as a novel therapeutic target for primary hypertension. The lentiviral vector containing human immunodeficiency virus 1 (HIV-1), the miR-126 gene knockdown viral vector (lenti-miR-126-KD), and control lentiviral vector (lenti-scramble-miR) were constructed. Spontaneously hypertensive rats were randomly divided into 4 groups, which received a high dose of lenti-miR-126-KD (1×108, n=5), low dose of lenti-miR-126-KD (1×107, n=6), scramble-miR (5×107, n=6), and PBS (n=6). Lentiviral vectors were injected into the tail vein. Data on the systolic blood pressure, diastolic pressure, mean arterial pressure, and heart rate were collected weekly. After 8 weeks of virus administration, the distribution of lentiviral vectors in different tissues was observed by fluorescence microscopy. Picric acid Sirius red and H&E staining were used to observe the target organ damage, and the ELISA kit was used to determine the serum nitric oxide (NO) content. The lentiviral vector was found to be constructed successfully. Eight weeks after the lentiviral vector injection, green fluorescent protein was observed in different tissues in each group. The blood pressure and heart rate were not significantly altered after lentiviral vector injection (P>0.05). No significant differences in the heart-to-body weight ratio among the four groups were observed (P=0.23). Picric acid Sirius red and H&E staining revealed that there was no significant difference in morphology among the four groups. No significant difference in the serum NO level among the four groups was noted (P=0.23). The miR-126 gene knockdown lentiviral vector was constructed successfully. No significant antihypertensive effect was observed by the knockdown of miR-126 for the treatment of primary hypertension. The target organs were not protected significantly after the treatment. The increased level of miR-126 expression in hypertensive patients may be due to a compensatory mechanism.


Medical Science Monitor | 2015

Impact of Cardiogenic Vomiting in Patients with STEMI: A Study From China

Zongsheng Guo; Xinchun Yang; Mulei Chen; Jiamei Liu; Li Xu; Yuan Zhang

Background Different patients with ST-elevation myocardial infarction (STEMI) have different symptoms. A third of them may have medical emergencies caused by symptoms such as vomiting and syncope. These concomitant symptoms may influence subsequent therapy and final outcomes. The aim of this study was to determine whether cardiogenic vomiting is a predictor of clinical outcomes in patients with STEMI. Material/Methods We classified 152 STEMI patients from different areas into 2 groups on the basis of vomiting: group A and group B. Their demographics and conditions of hospitalization were recorded. After follow-up, major adverse cardiac events (MACE) were regarded as study endpoints for the effect of cardiogenic vomiting in STEMI patients. Results We found no significant difference in demographic and clinical characteristics of the 2 groups (P>0.05). The hospitalized conditions of group A were more serious than in group B. During a follow-up of 6 months, MACE rate was higher in vomiting patients (42; 67.7%) compared with group B (25; 27.8%). Multivariate Cox regression analysis revealed that cardiogenic vomiting was an independent predictor of clinical outcomes. Conclusions Cardiogenic vomiting is a useful predictor of major adverse cardiac events in STEMI patients for the hospitalization and after discharge.


Heart | 2013

GW24-e0403 Autoantibodies against angiotensin II type 1 receptor-positive patients with heart failure have better clinical efficacy to perindopril treatment

Du Qian; Xin Wang; Zhiyong Zhang; Lin Xu; Jiamei Liu; Juan Zhang; Hua Wang; Jin Chen; Guilin Ma; Hakon Hakonarson; Aihua Hu; Lin Zhang

Objectives Previously, we reported that autoantibodies specific for the angiotensin II type 1 receptor (anti-AT1-AR) is implicated in the pathogenesis of congestive heart failure (CHF). We hypothesised that the presence of anti-AT1-AR is associated with the left ventricular function of CHF patients in response to perindopril. Methods Synthetic angiotensin II type 1 receptor (AT1-R) peptides were used as the target antigen. An ELISA was used to screen the sera of 156 CHF patients with NYHA class II-IV. The patients were then divided into positive or negative groups based on their anti-AT1-AR reactivity. Each patient of each group was subjected to an echocardiography and a 6-minute walk test. Performance at baseline and after one year of perindopril therapy with β-receptor blockers, diuretics, and digoxin were documented. Results A total of 138 patients completed the final analysis in this study, including 82 patients with (+) anti-AT1-AR and 56 patients with (–) anti-AT1-AR. Compared to the patients with (–) anti-AT1-AR, patients with (+) anti-AT1-AR had a greater improvement in left ventricular end-diastolic, end-systolic dimensions, and ejection fraction (all P < 0.05). Similar trends were also observed in patients subjected to a 6-minute walk test (P < 0.05) after one year of perindopril therapy in combination with standard treatment. CHF patients that were (+) anti-AT1-AR responded better to target perindopril dose than those that were (–) anti-AT1-AR (P < 0.01). After 5 years of follow-up, there was no significant difference for hospitalisation, death, or cardiovascular failures between patients with (+) anti-AT1-AR and (–) anti-AT1-AR. Conclusions Compared to (–) anti-AT1-AR, patients that were (+) anti-AT1-AR had a greater clinical therapeutic benefit on left ventricluar remodeling and function. This result potentially presents a novel biomarker of the renin-angiotensin-aldosterone system for assess of the level of receptor activation, as well as therapeutic intervention in patients with heart failure.


Heart | 2013

GW24-e0404 Proteomics screen to reveal molecular changes mediated by C722G missense mutation in CHRM2 gene

Hou Dong Yan; Ying Chen; Jiamei Liu; Juan Zhang; Hua Wang; Zhiyong Zhang; Xin Wang; Jin Chen; Hakon Hakonarson; Aihua Hu; Lin Xu; Lin Zhang

Objectives Previously, we reported that a missense mutation (C722G) in the M2-muscarinic acetylcholine receptor (CHRM2) geneis associated with familial dilated cardiomyopathy (DCM). However, the exact molecular mechanisms by the fundamental changes involved in the CHRM2 signalling pathways in patients with the C722G mutation are still not clear. Methods In this study, we generated CHRM2 and CHRM2-C722G lentiviral vector and applied to infect the CHO cells. Then we performed proteomic analyses by label free shotgun strategy and analysed the most changed proteins by the STRING 9.0 software–Known and Predicted Protein-Protein Interactions. Results A total of 102 proteins with at least 2-fold change in the cells transfected with CHRM2-C722G were identified, 42 proteins were up-regulated, whereas 57 proteins were down-regulated. These altered proteins belong to three broad functional categories: (i) metabolic [e.g. Ubiquitin-like modifier-activating enzyme 1, Cytosolic acyl coenzyme A thioester hydrolase, Malate dehydrogenase and Arginyl-tRNA synthetase]; (ii) cytoskeletal (e.g. Actin-related protein, Myosin light polypeptide 6 and Alpha-actinin-1) and (iii) stress response (e.g. heat shock protein 70, Ras-related protein Rab-10 and Ras GTPase-activating protein-binding protein2). Interestingly, the marked differences in the expression of selected eight proteins (change > 4.0-fold), including heat shock protein 70, Malate dehydrogenase, Sodium/potassium -transporting ATPase subunit alpha-1, Ubiquitin-like modifier-activating enzyme 1, et al were connected with many proteins related to apoptosis and immune/inflammatory response such as: FOS, BAX, MYC, TP53 and IL6, which are involved in the pathology of congestive heart failure. Conclusions We have carried out a full-scale screening of the proteomics research under condition of C722G mutation in the CHRM2 gene related to familial DCM and profiled the eight proteins which may be critical in cardiac dysfunction for future mapping.


BMC Cardiovascular Disorders | 2013

Perindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptor

Qian Du; Jinling Wu; Hua Wang; Xin Wang; Lin Xu; Zhiyong Zhang; Jiamei Liu; Juan Zhang; Jin Chen; Hakon Hakonarson; Aihua Hu; Lin Zhang

Collaboration


Dive into the Jiamei Liu's collaboration.

Top Co-Authors

Avatar

Lin Zhang

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Juan Zhang

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Hua Wang

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Lin Xu

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Xin Wang

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Zhiyong Zhang

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Jin Chen

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Xinchun Yang

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Aihua Hu

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Hakon Hakonarson

Children's Hospital of Philadelphia

View shared research outputs
Researchain Logo
Decentralizing Knowledge